Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Processa PharmaceuticalsPCSA -2.80%29 Cash-to-Debt is No Debt (1) as of Mar. 2026, which is 100% below its 10-year median of 30.49. GuruFocus rates PCSA with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,400 Biotechnology companies, Processa Pharmaceuticals ranks better than 73.5% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Processa Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2026 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Processa Pharmaceuticalscould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Processa Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
PCSA'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 30.49 Max: No Debt
Current: 65.04
During the past 13 years, Processa Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 30.49.
PCSA's Cash-to-Debt is ranked better than 73.5% of 1400
companies
in the Biotechnology industry
Industry Median: 6.57
vs PCSA: 65.04
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Processa Pharmaceuticals Cash-to-Debt Related Terms
Processa Pharmaceuticals Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Processa Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Processa Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Processa Pharmaceuticals's Cash-to-Debt falls into.
Processa Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
Processa Pharmaceuticals had no debt (1).
Processa Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2026 is calculated as:
Processa Pharmaceuticals had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
Processa Pharmaceuticals (PCSA) has a Cash-to-Debt of No Debt (1) as of Mar. 2026. This is 97% below median its historical median of 30.49. According to the industry distribution chart, Processa Pharmaceuticals ranks #371 out of 1400 companies in the Biotechnology industry, placing it in the top 26.5%.
Is Processa Pharmaceuticals' Cash-to-Debt too high?
Processa Pharmaceuticals' current Cash-to-Debt of No Debt (1) is 97% below median its 10-year median of 30.49. Based on the distribution chart, Processa Pharmaceuticals ranks #371 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Processa Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Processa Pharmaceuticals' Cash-to-Debt compare to BOLT and BRTX?
According to the Biotechnology industry distribution chart, Processa Pharmaceuticals ranks #371 out of 1400 companies for Cash-to-Debt. This puts Processa Pharmaceuticals in the upper half of its industry. The industry median Cash-to-Debt is 6.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.57, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Processa Pharmaceuticals's current Cash-to-Debt is No Debt (1), which is 97% below median its own 10-year median of 30.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Processa Pharmaceuticals stock overvalued right now?
Processa Pharmaceuticals (PCSA) has a current Cash-to-Debt of No Debt (1). The current Cash-to-Debt is No Debt (1), which is 97% below median its 10-year median of 30.49. Processa Pharmaceuticals' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current Cash-to-Debt is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
29GF Score
Get the complete analysis for PCSA
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCSA has been successfully added to your 
